slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 91,741-91,770
Pages 3,683
Rows per page 30
Component
91,741-91,770 of 110,471
08
Includes a biological pathway diagram and a specific 'Degrader Advantage' callout box.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
11
Includes both a longitudinal line chart of IRAK4 reduction and a grouped bar chart with a summary table for cytokine inhibition.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
The slide displays 12 bar charts representing log2(fold change) for specific genes across individual patients.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Focuses on partnership dynamics and clinical progress.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
27
Data presented as % change from C1D1 Predose. Includes time course line chart and dot plot for maximum degradation.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
28
Data from a clinical study of KT-333, showing biomarker response across different dose levels (DL1, DL2, DL3).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
29
Includes ASH logo and specific clinical trial metrics (DL levels, AE types).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
34
Comparison of KT-253 vs DS-3032 (SMI) across protein levels and tumor volume over time.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
37
Swimmer plot showing days on study for three patients, with corresponding CT scan imagery for one patient.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
38
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
03
The slide uses a list-based layout to present key company milestones and financial health.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Executive Summary1 hit
05
The slide uses a timeline framework to demonstrate long-term IP protection.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
The slide outlines a clinical development roadmap with specific trial types and status updates.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a list-based layout to present key company milestones and status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
31
MAD = Multiple Ascending Dose. PK = Pharmacokinetics.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
41
The slide highlights key preclinical efficacy outcomes for the drug candidate CTI-1601.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
42
Includes two charts: a bar chart for hFXN concentration and a dot plot with error bars for SDH activity.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
43
Data shows significant differences (****) between vehicle and CTI-1601 treated KO mice.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
44
The slide uses two line charts to demonstrate efficacy in two different cardiac metrics (Ejection Function and Fractional Shortening) over an 8-week period.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
03
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Attention1 hit
05
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart shows a stacked bar breakdown of U.S. vs EU sales over 6 quarters.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit